Single-cell spatial multiomics of tau neuropathology and cellular senescence in human brain sections

Our goal is to identify therapies for Alzheimer’s disease by studying its primary risk factor, advanced age. Profiling post-mortem human Alzheimer’s disease brains using high-resolution methods like GeoMx® Digital Spatial Profiler (DSP) and CosMx™ Spatial Molecular Imager (SMI) revealed a novel drug target linked to aging. Subsequent studies in transgenic mice, including spatial proteogenomic analyses, confirmed target engagement and efficacy, leading to clinical testing in older adults with Alzheimer’s disease. Evaluation of clinical trial samples with a custom nCounter® Gene Expression Panel yielded promising data, supporting Phase 2 clinical testing. This presentation will showcase key findings along this translational path.

The CosMx™ SMI and decoder probes are not offered and/or delivered to the Federal Republic of Germany for use in the Federal Republic of Germany for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof in a method used in fluorescence in situ hybridization for detecting a plurality of analytes in a sample without the consent of the President and Fellows of Harvard College (Harvard Corporation) as owner of the German part of EP 2 794 928 B1. The use for the detection of cellular RNA, messenger RNA, microRNA, ribosomal RNA and any combinations thereof is prohibited without the consent of the President and Fellows of Harvard College (Harvard Corporation).